DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,284,022 | +10.1% | 2,292,003 | +57.5% | 0.27% | +9.6% |
Q2 2023 | $42,946,552 | +71.2% | 1,455,322 | +33.7% | 0.25% | +83.1% |
Q1 2023 | $25,084,524 | -17.2% | 1,088,738 | 0.0% | 0.14% | -25.3% |
Q4 2022 | $30,277,804 | +67.6% | 1,088,738 | +84.9% | 0.18% | +54.2% |
Q3 2022 | $18,068,000 | +4.3% | 588,738 | 0.0% | 0.12% | +20.4% |
Q2 2022 | $17,327,000 | +506.9% | 588,738 | +563.5% | 0.10% | +512.5% |
Q1 2022 | $2,855,000 | -27.9% | 88,738 | 0.0% | 0.02% | -15.8% |
Q4 2021 | $3,958,000 | -11.6% | 88,738 | 0.0% | 0.02% | -5.0% |
Q3 2021 | $4,477,000 | -35.7% | 88,738 | 0.0% | 0.02% | -35.5% |
Q2 2021 | $6,961,000 | +37.4% | 88,738 | 0.0% | 0.03% | +40.9% |
Q1 2021 | $5,067,000 | -31.8% | 88,738 | 0.0% | 0.02% | -21.4% |
Q4 2020 | $7,433,000 | +108.7% | 88,738 | -10.7% | 0.03% | +100.0% |
Q3 2020 | $3,562,000 | +40.5% | 99,400 | -5.2% | 0.01% | +27.3% |
Q2 2020 | $2,536,000 | +38.1% | 104,900 | 0.0% | 0.01% | 0.0% |
Q1 2020 | $1,837,000 | – | 104,900 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |